Avantor's turnaround gains proof: guidance raised, orders up, APAC expansion
Turnaround shows up in the numbers Avantor beat second-quarter expectations and raised its 2026 sales and earnings guidance, as its VWR distribution unit returned to organic growth earlier than expected. That directly answers the biggest worry — that the company was shrinking — and is the main reason the stock jumped.
The guidance raise and beat are the core new event that changed the growth story.
Orders point to a second-half rebound The Bioscience & Medtech products unit posted double-digit order growth and a book-to-bill above 1, meaning orders are outpacing sales. Management expects that segment to grow again in the second half, a sign the worst of the bioprocessing slump may be passing.
Order growth and book-to-bill are the forward-looking evidence behind the recovery.
APAC single-use expansion adds growth Avantor widened availability of its RIM single-use bioprocessing products across Asia Pacific, made at its Changzhou, China plant. It deepens its reach in a key biopharma manufacturing region and supports the Revival strategy, though the near-term revenue contribution is not yet spelled out.
A concrete new market expansion that supports future demand.
Margins and debt still weigh on the story Even with better sales, gross margin fell about 120 basis points and adjusted operating margin dropped 170 basis points on lower volumes, mix, inflation and freight costs. Debt is still about $3.7 billion, though the company repaid $112 million, so the recovery is real but not yet clean.
The main counterweight: profits are still squeezed even as revenue stabilizes.